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Acupuncture is an alternative therapy to induce ovulation in women with polycystic ovary syndrome (PCOS), but there is no study
reporting the live birth rate following ovulation induction by acupuncture or its potential as an adjuvant treatment to clomiphene
citrate (CC). We assess the efficacy of acupuncture with or without CC in achieving live births among 1000 PCOS women in
Mainland China. This paper reports the methodology of an ongoing multicenter randomized controlled trial. The randomization
scheme is coordinated through the central mechanism and stratified by the participating sites. Participants will be randomized into
one of the four treatment arms: (A) true acupuncture and CC, (B) control acupuncture and CC, (C) true acupuncture and placebo
CC, and (D) control acupuncture and placebo CC. To ensure the quality and integrity of the trial we have developed a unique
multinational team of investigators and Data and SafetyMonitoring Board. Up to the end of April 2013, 326 subjects were recruited.
In conclusion, the success of this trial will allow us to evaluate the additional benefit of acupuncture beyond the first line medicine
for fertility treatment in PCOS women in an unbiased manner.
1. Introduction
Polycystic ovary syndrome (PCOS) is the most common
endocrine disorder in women of reproductive age. It is char-
acterized by ovulatory dysfunction, hyperandrogenism, and
polycystic ovaries (PCO) and affects 5–10%of premenopausal
women [1]. In addition to irregular menses, hirsutism, and
infertility, women with PCOS may display a number of
metabolic abnormalities including hyperinsulinemia, insulin
resistance, dyslipidemia, and obesity [2]. Clomiphene citrate
(CC) is considered as the first line treatment to induce
ovulation in women with PCOS. A compilation of published
results from 5,268 patients revealed an ovulation rate of 73%
per cycle per patient, pregnancy rate of 36% per patient,
and live birth rate of 29% per patient during a six-month
treatment [3].Womenwho do not ovulate while receiving the
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maximum 150mg dose are considered to be CC resistant and
those who do not conceive after an ovulatory response are
considered clomiphene failures. Both appear to be common
[4], necessitating the search for adjuvant therapies to treat
infertility in women with PCOS.
Inability of CC to induce ovulation is more likely in
patients who are obese, insulin resistant, and hyperandro-
genic compared with those who do respond [5]. The mech-
anism of CC failures may partly be explained by a peripheral
anti-estrogenic effect at the level of endometriumand cervical
mucus or by hypersecretion of luteinizing hormone (LH).
Side effects of CC are related to its combined estrogenic and
antiestrogenic properties, which include hot flushes, breast
discomfort, abdominal distension, nausea, vomiting, ner-
vousness, sleeplessness, headache, mood swings, dizziness,
hair loss, and disturbed vision [4]. Approximately 7% of
pregnancies resulting from CC-induced ovulation are twin
pregnancies and 0.5% are triplet pregnancies [6].
The choice of adjuvant treatments or second line
treatment is controversial. The benefit of combined met-
formin/CChas been called into question by themeta-analysis
[7]. Gonadotropin treatment can be offered as the second
line drug when anovulatory PCOS women fail to respond
to CC. The use of gonadotropin is more expensive than CC
and associated with a higher risk of multiple pregnancies
and development of ovarian hyperstimulation syndrome.
Ovarian drilling by diathermy or other methods is the
second line therapy with equal efficacy to gonadotropin [8].
However this treatment is also expensive and invasive. New
or additional treatments that are readily accessible, affordable,
and safe are needed.
Acupuncture is an integral part of Traditional Chinese
Medicine (TCM), which dates back to more than 3,000 years.
In recent years, the use of acupuncture within reproductive
endocrinology and infertility has gained increased popularity
worldwide [9–11]. From a physiological perspective, the effect
of acupuncture is most likely mediated via activation of
sensory nerve fibers, which in turnmodulate the sympathetic
activity to the ovaries and from the central nervous system
(CNS). Support for the theory that acupuncture, at least
in part, modulates sympathetic activity arises from the
findings that acupuncture decreases high ovarian expression
of sympathetic markers and increases ovarian blood flow, an
effect mediated as a reflex response via ovarian sympathetic
nerves and via CNS [12–14]. Further, both acupuncture and
exercise reduced high muscle sympathetic nerve activity in
women with PCOS [15, 16].
In PCOS women with ovulatory dysfunction, several
nonrandomized trials revealed that repeated acupuncture
treatments decreased total testosterone and other sex steroid
levels, reduced LH/follicle-stimulating hormone (FSH) ratio,
and improved menstrual frequency without negative side
effects [17–19]. In a randomized controlled trial (RCT),
fourteen acupuncture treatments, with combined electrical
and manual stimulation of the needles during 16 weeks and
16 weeks of physical exercise compared with no intervention,
improved menstrual bleeding pattern and decreased high
levels of sex steroid precursors, estrogens, androgens, and
glucuronidate androgen metabolites in women with PCOS
[20]. Acupuncture was superior to physical exercise when
compared directly after the treatment period. In a quasi-
randomized study, daily abdominal acupuncture during 6
months improved menstrual frequency and decreased circu-
lating testosterone more effectively than metformin during 6
months [21]. Recently in another RCT, 12 treatments of true
acupuncture were compared with control acupuncture using
placebo needles during 8 weeks and similar ovulation rates
were found in both groups of women with PCOS [22].
Findings from previous clinical and experimental studies
indicate that acupuncture may induce ovulation and improve
pregnancy in women with PCOS. However, the methodolog-
ical quality of these studies is of varying quality, and none
were designed to investigate pregnancy or more importantly
live birth. We sought to address these gaps in knowledge by
designing an RCT to examine the effects of acupuncture on
live birth in women with PCOS. The objective of the present
trial is to test the following three hypotheses in anovulatory
women with PCOS: (1) true acupuncture and CC are more
likely to result in live birth than control acupuncture and CC,
(2) control acupuncture and CC are more likely to result in
live birth than true acupuncture and placebo CC, and (3) true
acupuncture and placebo aremore likely to result in live birth
than control acupuncture and placebo CC.
2. Materials and Methods
2.1. Study Population. Subjects will be recruited from 25
hospitals across 13 provinces in Mainland China when they
seek treatments for ovulatory problems and pregnancies.
They will be eligible if they meet the following inclusion and
exclusion criteria. Informed consent will be obtained after
detailed explanation, and each will be given a copy of the
signed consent.
Inclusion criteria are as follows.
(1) Age of women between 20 and 40 years.
(2) Chronic oligomenorrhea or amenorrhea: oligomen-
orrhea is defined as an intermenstrual interval >35
days or <8 menstrual bleedings in the past year.
Amenorrhea is defined as an intermenstrual interval
>90 days.
(3) Hyperandrogenism (either hirsutism or hyperan-
drogenemia) or polycystic ovaries on ultrasound.
Hirsutism is determined by a modified Ferriman-
Gallwey Score ≥ 5 at screening examination [23].
Polycystic ovaries are present when there are ≥12
antral follicles (2–9mm) or ovarian volume >10 mL
on transvaginal scanning [24].
(4) Further, at least one patent tube and normal uterine
cavity shown by hysterosalpingogram, HyCoSy, or
diagnostic laparoscopy with chromotubation within
three years [25].
(5) Sperm concentration⩾ 15×106/mL and totalmotility
⩾ 40% or total motile sperm count ⩾ 10 million in the
semen analysis of the husband [26, 27].
(6) Agree to have regular intercourse, that is, 2-3 times
per week during the study period.
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Exclusion criteria are as follows.
(1) Exclusion of other endocrine disorders: A patients
with hyperprolactinemia ( defined as two prolactin
levels at least one week apart ⩾25 ng/mL) B Patients
with FSH levels > 15mIU/mL. A normal level within
the last year is adequate for entry. C Patients
with uncorrected thyroid disease (defined as TSH
<0.2mIU/mL or >5.5mIU/mL). A normal level
within the last year is adequate for entry. D Patients
diagnosed with Type I or Type II diabetes who are
poorly controlled (defined as HbA1c level > 7.0%),
or patients receiving antidiabetic medications such as
metformin, insulin, thiazolidinediones, acarbose, or
sulfonylureas. E Patients with suspected Cushing’s
syndrome.
(2) Use of hormonal or other medication including Chi-
nese herbal prescriptions in the past 3 months.
(3) Pregnancy within the past 6 weeks.
(4) Within 6 weeks postabortion or postpartum.
(5) Breastfeeding within the last 6 months.
(6) Not willing to give written consent to the study.
(7) Additional exclusion criteria are as follows.
(a) Patients on oral contraceptives, depot proges-
tins, or hormonal implants (including Implan-
on). A two-month washout period will be
required prior to screening for patients on these
agents. Longer washouts may be necessary for
certain depot contraceptive forms or implants,
especially where the implants are still in place. A
one-monthwashoutwill be required for patients
on oral cyclic progestins.
(b) Patients with liver disease defined as AST or
ALT > 2 times normal or total bilirubin >
2.5mg/dL. Patients with renal disease defined
as BUN > 30mg/dL or serum creatinine >
1.4mg/dL.
(c) Patients with hemoglobin < 10 g/dL.
(d) Patients with a history of deep venous throm-
bosis, pulmonary embolus, or cerebrovascular
accident.
(e) Patients with known heart disease that is likely
to be exacerbated by pregnancy.
(f) Patients with a history of, or suspected cervical
carcinoma, endometrial carcinoma, or breast
carcinoma. A normal Pap smear result will be
required for women 21 and over.
(g) Patients with a current history of alcohol abuse.
Alcohol abuse is defined as >14 drinks/week or
binge drinking.
(h) Patients enrolled into other investigative studies
that require medications, prescribe the study
medications, limit intercourse, or otherwise
prevent compliance with the protocol.
(i) Patients who anticipate taking longer than a
one-month break during the protocol should
not be enrolled.
(j) Patients taking other medications known to
affect reproductive function or metabolism.
These medications include oral contraceptives,
GnRH agonists and antagonists, antiandrogens,
gonadotropins, antiobesity drugs, Chinese
herbal formula, antidiabeteic drugs such asmet-
formin and thiazolidinediones, somatostatin,
diazoxide, angiotensin-converting-enzyme
(ACE) inhibitors, and calcium channel block-
ers.Thewashout period on all thesemedications
will be two months.
(k) Patients with a suspected adrenal or ovarian
tumor secreting androgens.
(l) Couples with previous sterilization procedures
(vasectomy, tubal ligation), which have been
reversed. The prior procedure may affect study
outcomes, and patients with both a reversed
sterilization procedure and PCOS are rare
enough that exclusion should not adversely
affect recruitment.
(m) Subjectswhohave undergone a bariatric surgery
procedure in the recent past (<12 months) and
are in a period of acute weight loss or have been
advised against pregnancy by their bariatric
surgeon.
(n) Patientswith untreated poorly controlled hyper-
tension defined as a systolic blood pressure
160mmHg or a diastolic 100mm Hg obtained
on two measures obtained at least 60 minutes
apart.
(o) Patients with known congenital adrenal hyper-
plasia.
2.2. Study Design. This is a multicenter, randomized, double-
blinded, controlled, 2 by 2 factorial clinical trial for PCOS
women in China, with study treatment during 4-month
cycles. Participants are randomized to receive either an initial
oral dose of 50mg of CC or placebo CC from day 3 to day 7 of
the cycle [4] in combination with one of the two acupuncture
procedures. The starting date for CC is not expected to
affect the treatment outcome [28]. In order to maintain the
double-blinding for the medication, CC and placebo CC
were packaged in identically appearing numbered study kits
which were then directly shipped to each clinical site. For
acupuncture, all patients will receive either true or control
acupuncture treatment.
2.3. Randomization. Randomization takes place as soon as
the eligibility requirements aremet. Participants are random-
ized into one of the four treatment arms: (1) true acupunc-
ture and CC, (2) control acupuncture and CC, (3) true
acupuncture and placebo CC, and (4) control acupuncture
andplaceboCCby an interactive online computer program in
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a central office. Using a 1 : 1 : 1 : 1 treatment ratio, there will be
250 women assigned to each treatment group and we expect
the dropout rate would be 20%. The randomization is strati-
fied within each of the participating sites by a random block
algorithm. The data coordinating center (DCC) statisticians
generated and validated the randomization scheme for the
study before it was implemented in a web-based database
system, and the study coordinator at each participating site
logs on the web-based system to retrieve the randomization
number after a patient is ready for it. The CC and placebo
CC assignments are double-blinded, unknown to patients
and study investigators except the DCC data manager. The
true and control acupuncture treatments are known only to
the TCM specialist (besides the DCC data manager) of the
participating site that performs the randomized procedure.
2.4. Acupuncture Treatments. Two fixed acupuncture pro-
tocols, true acupuncture and control acupuncture, are used
in the study. The rationale of true acupuncture is based on
existing data from experimental studies and on previous RCT
in women with PCOS [20, 22]. The control acupuncture
is chosen in contrast to true acupuncture and designed
in such a way that it is thought to be less effective for
ovulation induction. The two acupuncture protocols follow
the STRICTA recommendations [29].
Clinical experience and training of acupuncturists may
affect the outcome [30]. To assure that the intervention is
performed in a standard manner, all acupuncturists with
TCM certificate and 1 year experience receive a study specific
theoretical course and a study specific practical training,
totally 3 times before the beginning of the study, 1–3 days per
time, and 1 time, four hours after one month of the study
beginning. All acupuncturists have to pass the theory and
practical tests. In China, acupuncturists perform acupunc-
ture in over 50 patients per day, thus they will rapidly be
experienced. Furthermore, while they are trained for only
a short time for this study acupuncture protocols, they are
graduate students in Chinese medicine and have received
general acupuncture training during their studies. In this
study, 35 acupuncturists have been trained both in theory and
practice of acupuncture, and there is at least one designated
acupuncturist at each participating site.
All participants receive acupuncture treatment twice a
week and each treatment session can be separated by an
interval of 2–4 days, with a maximum of 32 treatment
sessions during 16 weeks. Each treatment session lasts for
30 minutes. Acupuncture treatment will start on day 3 after
a spontaneous period or a withdrawal bleeding following
progestin, when starting with CC/placebo tablet. Participants
will be contacted by phone if they miss the appointment as
scheduled. If they miss appointments in the early part of the
cycle, more appointments will be arranged in the later part
to compensate the missing part. Missed appointments will
be clearly documented in the record for analysis later. If the
participants miss 6–8 acupuncture treatments (3-4 weeks),
she should be scheduled not to take CC or CC placebo
and have this treatment cycle “cancelled” until she can get
acupuncture.
In true acupuncture, needles are made of stainless steel
(Hwoto, Suzhou Medical Appliance Fact., Suzhou, China);
0.25 × 30mm and 0.30 × 40/50mm needles are inserted
to a depth of 15–35mm in acupuncture points located in
abdominal and leg muscles with same somatic innervations
as the ovaries and uterus [31]. Two sets of acupuncture points
alternated every other treatment.The first set of acupuncture
points consists of conception vessel (CV) 3, CV 6, and
stomach (ST) 29 bilaterally and in the muscles below the
knee, spleen (SP) 6, and SP 9 bilaterally; all segmental points
with somatic innervations correspond to the ovaries and the
uterus (Table 1). Needles are also placed in extrasegmental
acupuncture points that do not innervate the ovaries and
uterus: large intestine (LI) 4 bilaterally and governor vessel
(GV) 20. Abdominal and leg points were selected because
they have been demonstrated to increase ovarian blood flow
response [13, 14]. Points in hands and head have been used
in previous studies [20] and were selected to potentiate
the effect of the segmental points. Furthermore, they have
been demonstrated in experimental studies to act via central
nervous system [32].
A total of 11 needles are placed, and all are stimulated
manually by rotating the needle quickly with thumb and fore-
finger to evoke needle sensation (de qi) once when inserted.
De qi reflects activation of afferent nerve fibers and can be
described as numbness, distension, or electrical tingling.The
points CV 3, CV 6, ST 29, SP 6, and SP 9 are thereafter
connected to electrical stimulator (AS Super 4Digital, schwa-
medico GmbH, Ehringshausen, Germany) and stimulated
with low-frequency, 2Hz, 0.3ms pulse length and the inten-
sity is adjusted to produce local muscle contractions without
pain or discomfort. Needles not connected to the electrical
stimulator are manually stimulated by rotating the needle to
evoke needle sensation every 10min, in a total of 4 times. If
the sensation of de qi does not occur, manual manipulation
techniques can be applied to promote it (such as “plucking,”
“shaking,” or “trembling”). The second set of acupuncture
points consists of 13 needles placed in segmental abdominal
points; ST 25 and 29 bilaterally (electrical stimulation) and
CV3 and CV6 (manual stimulation), leg points; SP6 and liver
(LR) 3 bilaterally (electrical stimulation). Extrasegmental
points are pericardium (PC) 6 bilaterally and GV20 (both
manual stimulation).
In control acupuncture, two needles will be inserted
superficial to a depth of <5mm in each arm, one in each
shoulder and one in each upper arm at nonacupuncture
points, without any stimulation (Table 1). Needles are made
of stainless steel (Hwoto, Suzhou Medical Appliance Fact.,
Suzhou, China), 0.20 × 20mm. Electrodes will be attached
to the needles and the stimulator is turned on at an intensity
of zero (no active current) in order to mimic electrical
stimulation in the true acupuncture group. No stimulation of
the needles is performed.
Participants are monitored weekly by urinary pregnancy
test and serum progesterone levels. The dose of oral medica-
tionmay be increased by 50mg in the absence of ovulation or
maintained in the presence of ovulation.The maximum dose
of CCwill not exceed 150mg/cycle.The treatment lasts for up
to 4 month cycles.
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Table 1: Acupuncture points, stimulation, localization, tissue in which needles are inserted, and innervations area in true acupuncture which
consists of two protocols that are alternated every other treatment (A and B) and control acupuncture.
True acupuncture
point Stimulation Localisation Muscle Muscle innervation
Protocol A
Zhongji; CV3 EA 4 cun caudal to the umbilicus Fibrous tissue, linea alba L1
Qihai; CV6 1.5 cun caudal to the umbilicus Fibrous tissue, linea alba Th11
Guilai; ST29 EA 1 cun cranial to the pubic bone and2 cun lateral to the midline M rectus abdominis Th6-12
Sanyinjiao; SP6 EA
3 cun proximal to the medial
malleolus
Mm. flexor digitorum longus,
tibialis posterior L4-5, S1-2
Yinlingquan; SP9 Below medial tibia condyle M. gastrocnemius S1-2
Hegu; LI4 DeQi 4 times On the highest point at m.interosseus dorsalis
Mm. interosseus dorsalis I,
lumbricalis II, adductor pollicis C8, Th1
Baihui; GV20 DeQi 4 times On the top of the head Aponeurosis epicranii C2-3, N. trigeminus
Protocol B
Zhongji; CV3 DeQi 4 times 1 cun cranial to the pubic bone inthe midline Fibrous tissue, linea alba L1
Qihai; CV6 DeQi 4 times 1.5 cun caudal to the umbilicus Fibrous tissue, linea alba Th11
Guilai; ST29 EA
1 cun cranial to the pubic bone and
2 cun lateral to the midline M rectus abdominis Th6–12
Tianshu; ST25 2 cun lateral to the midline at thelevel of the umbilicus M rectus abdominis Th6–12
Sanyinjiao; SP6 EA
3 cun proximal to the medial
malleolus
Mm. flexor digitorum longus,
tibialis posterior L4-5, S1-2
Taichong; LR3 Between metatarsale I & II, justdistal to the caput M. Interosseus dorsalis I S2-3
Neiguan; PC6 DeQi 4 times
2 cun proximal to processus
styloideus radii, between the
tendons of palmaris longus and
flexor carpi radialis
M. flexor digitorum superficialis C8, Th1
Baihui; GV20 DeQi 4 times On the top of the head Aponeurosis epicranii C2-3, N. trigeminus
Control acupuncture
point Stimulation Localisation Skin Skin innervation
No known point Sham EA On top of acromion Skin C3-4,n. supraclavicularis
No known point Sham EA On humerus, behind LI14 Skin
C5-6,
n. cutaneous brachii
lateralis
CV: conception vessel; ST: stomach; SP: spleen; LI: large intestine; GV: governor vessel; LR: liver; PC: pericardium.
2.5. Study Specific Visits and Procedures. Each specific visit
and measurement is summarized in Table 2. Baseline mea-
sures include fasting FSH, LH, total testosterone (T), estradiol
(E2), sex hormone binding Globulin (SHBG), dehydroepi-
androsterone sulfate (DHEAS), glucose and insulin concen-
trations, cholesterol, triglycerides, high-density lipoprotein
cholesterol (HDL-C), low-density lipoprotein cholesterol
(LDL-C) and height, weight, hip, waist measurements, and
vital signs. Neither cervical mucus nor endometrial lining
will be monitored in this large clinical trial as these are not
routinely monitored in clinical practice. Also questionnaires
for assessments of health related quality of life (QOL) are
filled in: the short form 36 (SF 36) [33], the Polycystic
Ovary Syndrome Questionnaire (PCOS-QOL) [34], and the
Chinese Quality of life (ChQOL) [35]. Questionnaires for
symptoms of anxiety and depression are Zung Self-Rating
Anxiety Scale (SAS) [36] and Zung Self-reported Depression
Scale (SDS) [37]. All questionnaires used in this trial are
validated scales.
The TCMdiagnosis will bemade by an experienced TCM
doctor in each participating site according to a standard
questionnaire. Syndrome differentiation in TCM is the com-
prehensive analysis of clinical information gained by the four
main diagnostic TCM procedures: observation, listening,
questioning, and pulse analysis [38]. In PCOS, patients are
empirically differentiated to be four categories: (1) phlegm-
dampness syndrome, (2) blood stasis syndrome, (3) phlegm
and blood stasis, and (4) liver stagnation [39]. The TCM
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Table 2: Overview of the study visits.
Screening visit Baseline visit Week 1 Week 2 Week𝑁 + 1 Week 16 End oftreatment visit
Visit # 1 2 3 4 5 6 𝑁 𝑁 + 1 33 34 35
Sign consent ×
History × ×
Urine pregnancy test × × × × × × × × ×
Physical examination × ×
Transvaginal ultrasound × ×
Semen analysis ×
Hysterosalpingogram ×
Safety eligibility lads × ×
Fasting phlebotomy for study parameters × ×
Depression, anxiety, and quality of life
questionnaires × ×
Credibility check questionnaire × × ×
Progesterone assay × × × × × ×
HCG assay × × × × × ×
Acupuncture treatments (twice weekly) × × × × × × × ×
Assess adverse events and concomitant meds × × × × ×
Credibility check questionnaires are completed on the third acupuncture treatment and the last acupuncture treatment.
HCG: HCG concentrations will be measured once a week during the study period. If serum HCG concentration is elevated above 10 IU/L, pelvic ultrasound
will be arranged 2 weeks later for the number of the gestational sacs and the viability of the pregnancy.
diagnosis will not affect the treatment protocol, and it will
enable us to explore its effect on the treatment success in a
secondary analysis.
All baseline measures will be repeated in all subjects at
the end of visits. Blood samples (including the safety labs)
will be collected and shipped to the core lab. Credibility
check questionnaires are completed on the third acupuncture
treatment and the last acupuncture treatment [40–42].
2.6. Responders. Responders are defined as having at least
one weekly elevated serum progesterone level indicative of
ovulation, that is, >3 ng/mL [43]. A woman who has ovulated
will be followed weekly until she has a period or a positive
pregnancy test. Responders will continue at the same dose of
CC or placebo until pregnancy, or a total of four cycles are
reached.
2.7. Nonresponders. No response is defined after 4 weeks
of CC/Placebo CC administration and true acupunc-
ture/control acupuncture with 3 consecutive weekly negative
progesterone and hCG levels. Ovulation will bemonitored by
weekly serum progesterone level and ultrasound monitoring
will not be performed as in a previous study [4].Then during
the fifth week a higher dose consisting of one more tablet
per day (up to 3 tablets per day at third or fourth cycles, if
they remain nonresponders) is given for 5 days, together
with 2 weekly sessions of acupuncture. If there is no period
after 3 weeks and the woman is not pregnant, CC 100mg
or 2 placebo tablets will be given daily from day 3 to day 7.
If there is again no period after 3 weeks and the woman is
not pregnant and not ovulating by progesterone levels, CC
150mg or 3 placebo tablets will be given daily from day 3 to
7. The same CC dose will be continued in the next cycle if
she is shown to have ovulation. A maximum of CC 150mg
or 3 placebo tablets daily are to be given even if she does
not ovulate during the study period. Nonresponders will not
receive progesterone for withdrawal bleeding before a higher
dose of CC unless at discretion of the site investigator.
2.8. Pregnancy Visits. Serum progesterone and hCG levels
are determined locally at sites to document ovulation and
pregnancy during weekly visit for acupuncture treatment.
Serial serum hCG level will be checked on a weekly basis if
pregnant. Serum beta hCG > 10 IU/L is usually considered
to be positive and indicates pregnancy. Pelvic ultrasound
will be arranged to confirm the number and location of the
gestational sac(s) when serum hCG is around 1500 IU/L or
clinically indicated. Then pelvic ultrasound will be arranged
every twoweeks until viability of the pregnancy is determined
by visualization of fetal heart motion. Pregnant subjects will
be referred to the obstetrics unit and follow-up scans will be
performed at week 18–24, 32, and 36 or at the discretion of
the obstetrician.
We do not encourage the pregnant subjects to take
any drugs during pregnancy. However, in Mainland China,
pregnant women may be given many medications including
TCM when they present with the risk of miscarriage. In
this trial, pregnant women who presents with threatened
miscarriage or are considered to have a significant risk for
miscarriage can be given oral Duphaston (10mg twice a day,
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Solvay Pharmaceuticals B.V.) till 12 weeks of gestation or 1
week after the vaginal bleeding stops as some studies [44–46]
have shown benefit of Duphaston in threatened miscarriage.
This information will be documented in the record form. No
other medications including hCG, herbal medications, and
acupuncture will be given by the investigators.
2.9. End of Treatment Visit. At the end of study, a visit
will be arranged for all women. The end of treatment visit
should be performed as early as possible in pregnant women.
A brief physical examination including acne and hirsutism
assessment and a final assessment of adverse events and
concomitant medications will be performed. Subjects will
return the remaining study drug and their journal logs. All
baseline measures will be repeated in all subjects.
The blood samples done at the baseline visit and the end
of the treatment visit will be shipped to the core laboratory
for analysis.
2.10. Establishment of a Pregnancy Registry. The outcomes of
all pregnancies will be followed after delivery or termination
of gestation. We will review pregnancy and birth records of
the mother and of the fetus to establish neonatal morbidity
and mortality and the presence of fetal anomalies. We
will extract from these records concomitant medical and
obstetrical conditions, exposure information on all other
medical products used, including prescription products,
over-the-counter products, dietary supplements, vaccines,
and insertable or implantable medical devices. We will file
individual case reports for all congenital anomalies, which
will be reported as serious adverse events. The ectopic
pregnancies will be identified by serial hCG monitoring
and pelvic ultrasound examination. The doctors performing
pelvic ultrasound are blinded to the treatment groups.
2.11. Sample Size Calculations. The overall live birth rate
for women to receive CC is estimated to be 20% during
the 4-month period according to Chinese Obstetrics and
Gynecology (Second Edition). Due to lack of existing data
on the effectiveness of acupuncture, we cannot rely on
the literature for samples size determination. Instead we
hypothesize that the order of effectiveness of the treatments
is as follows:
True acupuncture andCC>Control acupuncture and
CC,
control acupuncture and CC > True acupuncture and
placebo CC,
true acupuncture and placebo CC > Control acu-
puncture and placebo CC.
The respective live birth rates are projected with 10% differ-
ence as follows and the average rate among four arms is 15%
(Table 3).
Using a two-sided trend test and with an effective sample
of 200 per group, our study is designed to have >80% power
at the significance level of 0.015 (we have three primary
hypotheses). The sample size has been inflated from 200 to
Table 3: The respective live birth rates in each intervention.
Interventions True acupuncture Control acupuncture
CC 𝐴 = 25% 𝐵 = 15%
Placebo CC 𝐶 = 15% 𝐷 = 5%
250/arm to allow for a dropout rate of 20%, totally 1000 cases
for four arms.
There have been multiple trials to study the effects of
CC in PCOS women. The primary aim of this trial is not
to reassess the efficacy of CC. The aim is to elucidate the
additional efficacy of acupuncture in combination with CC,
or acupuncture alone. Acupuncture is compared with CC
because CC has been demonstrated to be superior to met-
formin [4]. The previous study design is used as a role model
since it was the best executed andmost cited trials in this area.
Dr. Legro chairs the Steering Committee of this trial, and Dr.
Zhang leads the DCC for another trial using CC in PCOS
women.Theyhave considered all related studies, although the
power calculation involved inevitably some assumptions.The
significance level of 0.015 is approximately 0.05/3 because in
this study the overall significance level is controlled to 0.05
after correcting for the multiple comparisons involving three
primary hypotheses.
2.12. Data Analysis. The primary outcome is the live birth
rate. Secondary outcomes include (1) ovulation rate; (2)
ongoing pregnancy rate at gestation 8–10 weeks; (3) multiple
pregnancy rate; (4) miscarriage rate: loss of an intrauterine
pregnancy before 20 completedweeks of gestation; (5) change
in hormonal profile: FSH, LH, T, SHBG, and DHEAS; (6)
change in metabolic profile: glucose and insulin concentra-
tions, cholesterol, triglycerides, HDL-C, and LDL-C; (7) side
effect profile; (8) change in QOL; (9) change in symptoms of
anxiety and depression; and (10) credibility assessments.
The analysis will use an intent-to-treat (ITT) approach
to examining differences in the live birth rates among the
four treatment arms. Primary efficacy analysis will be done by
comparing the treatment groups with respect to the primary
outcome of live birth using the Pearson Chi-square test.
For the secondary, supportive analysis, we will fit a logistic
regressionmodel to compare the treatment arms with respect
to the primary outcome of live birth, adjusting for other
factors such as randomization stratification of study site
and prior exposure to study medications. The analysis of
other secondary outcomes measured over time will entail the
application of statistical methods that have been developed
for correlated data since repeated observations will be made
over time on each individual. For secondary outcomes such as
hormone levels, a linear mixed-effects model will be fit where
themain independent variables will be treatment group, time,
and their interaction as well as the designed randomization
stratification factors as covariates. Logistic regression models
will be used in secondary analyses to evaluate the predictive
value of treatment arm, clinical site, prior exposure to
CC, body mass index, and other explanatory variables on
binary outcomes (e.g., singleton live birth, abortion). Cox
proportional hazards models and a Kaplan-Meier method
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will be applied to compare time to pregnancy in the treatment
groups.
Adverse events will be categorized and percentage of
patients experiencing adverse events and serious adverse
events in this trial will be documented. Chi-square tests will
be performed to examine differences in the proportion of
total and categories of adverse events within each treatment
arm. For each Data and Safety Monitoring Board (DSMB)
report, a list and summary of the reported adverse events will
be presented in a blinded fashion, unless otherwise formally
requested. Unblinding of treatments will take place after all
participants have delivered or reported final outcomes to the
DCC or when there are medical emergencies.
3. Results
3.1. Trial Registration and Conduct. The trial has been regis-
tered at clinicaltrials.gov (NCT01573858) as well as the Chi-
nese clinical trial registration site (http://www.chictr.org/cn/;
ChiCTR-TRC-12002081), prior to the start of randomization.
The study protocol, the manual of operations and proce-
dures (MOP), CRFs, and informed consent forms have been
reviewed and approved by each site participating in the study.
They are in both English and Chinese versions. The principal
investigators (PIs) of the protocol and the grants supporting
the study are Professor Xiaoke Wu and Professor Lihui Hou
of Heilongjiang University of Chinese Medicine. Professor
Heping Zhang at Yale University leads the DCC with the
help of personnel from Heilongjiang University of Chinese
Medicine. All study sites are monitored on a regular basis,
the quality of data is tracked, and protocol deviations and
violations are reported.
3.2. Study Funding, Governance, andData Sharing. The study
is funded by National Public Welfare Projects for Chinese
Medicine and National Trial Base for TCM and is led by a
steering committee consisting of the two PIs, the leader of
theDCC, an independently-selected chair (Professor Richard
S. Legro of Penn State College of Medicine), site leaders
and investigators, and other selected experts. Each of these
individuals has one vote. Decisions are reached by majority
consensus and a formal vote. The steering committee meets
three times a year face to face and communicates through
phone conferences or emails regularly. Additionally there are
subcommittees including a protocol committee, a recruit-
ment committee, and publication committee.
There is an independent DSMB, which has conferences
regularly via phone to review the conduct and results of
the trial. The DSMB consists of both Chinese and Amer-
ican members, and reports are prepared in both Chinese
and English. The DSMB reviews the protocol and study
progress and makes recommendations during the course of
this trial. For example, it reviews immediately any serious
adverse events and adjudicates them. The DSMB also could
recommend termination of the trial for a variety of reasons
including poor recruitment, adverse effects of study medica-
tions, or a clear trend in one of the blinded treatment arms
in live births exceeding our expectations.There are no formal
stopping parameters for this trial.
3.3. Study Progress and Recruitment. The targeted duration of
recruitment will be 18 months and 25 hospitals at 21 sites are
involved. In order to achieve our enrollment goal of 1,000 ran-
domized subjects, each site must contribute 40–50 subjects,
which amounts to about one recruited subject per site per
week. There are a four-month treatment period and another
nine-month period to follow up the pregnancy outcome.
Therefore from the initial recruitment to the completion of
the follow-up, a total of 31 months (2.5 years) will be required
to complete the study.Up to the end ofApril 2013, 326 subjects
were recruited.
4. Discussion
This clinical trial is to test the efficacy of acupuncture with
or without CC on live birth in PCOS women suffering from
ovulatory dysfunction. Previous clinical and experimental
studies indicate that acupuncture may induce ovulation and
improve pregnancy in these women. In the design of an
acupuncture trial it is of great importance to define an
adequate dose of acupuncture for the specific condition to
be studied by taking all existing clinical and experimental
findings into account [47], and to follow the STRICTA
guidelines [29]. Further this clinical trial consists of a unique
collaboration among investigators from China mainland,
Hong Kong, Sweden, and the United States, with a similar
China-US DSMB to oversee the trial. We have created study
source documents in both Chinese and English andmeetings
and materials exist simultaneously in both languages. This
international collaboration has presented us with unique
opportunities (such as attracting expertise and resources
from different international institutions) and challenges (e.g.,
coordinating activities in different time zones and training
investigators who have limited experience in multicenter
studies). As a result, in order to uphold the highest ethical
standard and data quality, communication and repeated
trainings have been extremely important.
In this study, all acupuncture treatments are given by
well-trained TCM doctors who received training in PCOS,
theoretical and practical acupuncture for our protocol. This
training included the reviews of previous clinical and exper-
imental studies and discussions with clinicians and the
steering committee members. Before the start of the study,
we conducted a one-day study-specific education, including
theoretical sessions with a Western Medical approach to
acupuncture physiology, practical sessions with demonstra-
tions of true and control acupuncture, and lectures on
research methodology with focus on RCT. Periodic updates
have been conducted on an annual basis. Importantly, the
DCC personnel have been trained at Yale University Collab-
orative Center for Statistical Science for the RCT conduction
(e.g., coordination, reporting, and data management), and
clinical investigators have been trained at Harbin and Beijing.
Three control procedures are commonly used in ac-
upuncture clinical trials: waiting-list, nonpenetrating needle,
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and needle-insertion (superficial or deep) controls. Waiting-
list control was more frequently used in earlier RCTs. Non-
penetrating sham needle control, also known as “placebo
control,” with a device that looks and feels like a real
acupuncture needle but has a blunted tip that retracts into a
hollow shaft handle and touches the skin without penetration
[48] and needle-insertion control, with superficial needle
placement at acupuncture points or at nonpoint or “wrong”
point, or deep needle placement at “wrong points” [49, 50]
are all frequently used control situations. Importantly, none of
these control procedures are inert. As previously mentioned,
the design of true acupuncture is based on existing data from
experimental studies, on a previous RCT in PCOS women
[20], and on an unpublished RCT registered at ClinTrial.gov
(NCT00921492).
The control acupuncture is chosen in contrast to true
acupuncture and designed in such way that we believe
it is least effective. The needles used in control acupunc-
ture, which are thinner and shorter than those in true
acupuncture, are inserted superficially in the skin without
any stimulation, one in each shoulder and on in each upper
arm at nonacupuncture points. Placement of needles in the
control acupuncture is unlikely to induce ovulation inwomen
with PCOS. The electrodes are attached to the needles but
without any stimulation in order to mimic EA in the true
acupuncture. The use of control acupuncture is not only
to keep the study investigators (except the acupuncturists)
blinded to the treatment but also to let the participants know
that a certain acupuncture was performed to minimize the
bias of the psychological effects receiving or not receiving a
perceived effective acupuncture treatment. The participants
are informed that two acupuncture protocols are tested, but
they do not know which one is better in achieving ovulation
and live birth.
We have further created a unique study team consisting
of experts in Western and TCM, clinical trials, biostatistics,
and ethics, and developed a multilanguage infrastructure to
conduct and monitor the trial. This model both serves to
provide additional oversight and quality control to the trial
but also allows for the mutual education of all participating
investigators in areas where their previous training or expe-
rience was limited.
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